phrykt

Atea Pharmaceuticals, Inc. (AVIR): who owns it and who trades it

As of Nov 16, 2026, AVIR insiders reported 1 purchase worth $25.4K in the last 12 months. The largest buyer was Polly A. Murphy (Director), with $25.4K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Atea Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AVIR

124 funds and institutions reported AVIR shares worth $279M at the end of Q2 2026, about 75% of the company. The largest holder is FMR LLC (Fidelity) with 15.1%.

Funds and institutions (13F) 75%Everyone else 25%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.1%
BlackRock, Inc.10.9%
BML Capital Management, LLC8.7%
Tang Capital Management LLC6.0%
Vanguard Capital Management LLC3.7%
Bain Capital Life Sciences Investors, LLC2.6%
Acadian Asset Management LLC2.6%
Geode Capital Management, LLC2.5%
State Street Corp2.1%
Two Sigma Investments, LP1.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)12.00M15.07%$55.8M+0%
BlackRock, Inc.8.72M10.94%$40.5M+3%
BML Capital Management, LLC6.95M8.73%$32.3M-2%
Tang Capital Management LLC4.81M6.04%$22.4MNo change
Vanguard Capital Management LLC2.96M3.72%$13.8M-9%
Bain Capital Life Sciences Investors, LLC2.08M2.61%$9.7M-12%
Acadian Asset Management LLC2.04M2.55%$9.5M+29%
Geode Capital Management, LLC1.96M2.46%$9.1M+12%
State Street Corp1.65M2.07%$7.7M-2%
Two Sigma Investments, LP1.51M1.89%$7M-19%
Dimensional Fund Advisors LP1.30M1.63%$6M+4%
Renaissance Technologies LLC1.13M1.42%$5.3M-3%
Rosalind Advisors, Inc.1.07M1.34%$5M-9%
JPMorgan Chase & Co945,9181.19%$4.4M–
Northern Trust Corp755,2390.95%$3.5M+29%
Morgan Stanley719,5140.90%$3.3M-2%
Vanguard Portfolio Management LLC630,1850.79%$2.9M+13%
Charles Schwab Investment Management Inc610,6070.77%$2.8M+2%
Sixth Street Partners Management Company, L.P.610,6070.77%$2.8M–
Goldman Sachs Group Inc530,8560.67%$2.5M-10%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AVIR insiders reported $25.4K of open-market purchases and $0 of sales.

Purchases, 12 months
$25.4K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
May 18, 2026
Filed May 21, 2026

Purchases and sales by month

$25.4K$25.4KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 18, 2026Polly A. MurphyDirectorPurchase6,100$4.17$25.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Polly A. MurphyDirector$25.4K–May 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AVIR short interest

Low short interest. 3.8% of AVIR shares are sold short: about 1 share in 27. Over the last 12 reports the number of shares short went down 60%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.01M AVIR shares were sold short, 3.8% of the shares outstanding, down 2.0% from the report before. At the average daily volume of 315,089 shares, buying them all back would take about 9.6 trading days (days to cover).

Shares short, % of all shares

3.75%May 15Oct 3010.7%

Days to cover

9.6May 15Oct 3045.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.01M3.75%-2%315,0899.6
Oct 15, 20263.07M3.83%-61%287,22410.7
Sep 30, 20267.89M9.83%+3%304,91825.9
Sep 15, 20267.63M9.51%-0%279,46227.3
Aug 31, 20267.66M9.56%-0%186,20741.2
Aug 14, 20267.67M9.56%+2%288,34526.6
Jul 31, 20267.53M9.45%-3%417,47418.0
Jul 15, 20267.76M9.74%+11%340,92522.8
Jun 30, 20266.99M8.77%-1%435,95716.0
Jun 15, 20267.07M8.88%-6%244,77928.9
May 29, 20267.53M9.45%-1%314,52523.9
May 15, 20267.59M9.53%+1%384,81419.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Atea Pharmaceuticals company events

Atea Pharmaceuticals filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Nov 9, 2026AgreementAtea Pharmaceuticals, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc., as agent, and the lenders party thereto, providing for term loans in an of up to $200.0 million, subject to the terms and conditions set forth therein. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jun 22, 2026VoteReported shareholder vote results. Filing
  5. May 12, 2026ResultsReleased financial results. Filing
  6. Mar 5, 2026ResultsReleased financial results. Filing
  7. Jan 8, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Atea Pharmaceuticals financials

Famous investors that hold AVIR

3 of the 50 well-known investors we track reported holding AVIR in their latest 13F filing. The largest position is Jim Simons's, worth $5.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.09M$5.7M0.0%-3%
Israel Englander · Millennium ManagementQ3 2026159,884$833K0.0%-48%
Ken Griffin · Citadel AdvisorsQ3 202614,850$77.4K0.0%-91%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AVIR in the last 120 days.

FiledHolderFormStake
Nov 13, 2026JPM Partners LLC13G/A6.4%
Nov 13, 2026JPM Partners LLC13G/A6.4%
Oct 6, 2026TANG CAPITAL MANAGEMENT, LLC13G6.0%
Oct 6, 2026TANG CAPITAL MANAGEMENT, LLC13G6.0%

Questions about Atea Pharmaceuticals, Inc. (AVIR) stock

Who owns the most AVIR stock?

The largest reported owner of Atea Pharmaceuticals, Inc. (AVIR) is FMR LLC (Fidelity), with 15.1% of the company. In total, 124 funds and institutions reported holding AVIR at the end of Q2 2026, together about 75% of the shares. See the largest owners.

Are AVIR insiders buying or selling?

In the last 12 months, AVIR insiders reported 1 open-market purchase worth $25.4K and no sales. The latest trade was on May 18, 2026. See every trade.

What is the short interest in AVIR?

As of Oct 30, 2026, 3.01M AVIR shares were sold short, 3.8% of the shares outstanding, down 2.0% from the report before. At the average daily volume of 315,089 shares, buying them all back would take about 9.6 trading days (days to cover). See the history.

Which famous investors hold AVIR?

3 of the 50 well-known investors we track reported AVIR in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $5.7M. See all holders.

Executive pay

Atea Pharmaceuticals's chief executive was paid a total of $3.4M for the year ended Dec 31, 2025, down 19% from $4.2M the year before. In the last 12 months, Atea Pharmaceuticals's executives and directors bought $50.9K of stock on the open market and sold none.

Chief executive, total pay$3.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.